Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Oct 4

PMID 37790070

Authors

Eren Arslan Davulcu

Nur Akad Soyer

Filiz Vural

Affiliations

Soon will be listed here.

Abstract

Introduction: Allogeneic stem cell transplantation (ASCT) is a crucial therapeutic strategy for hematological and non-hematological disorders. Poor graft function (PGF) after ASCT presents a critical challenge that does not have a standardized treatment approach. A thrombopoietin-mimetic oral drug eltrombopag shows promise in some bone failure syndromes. This study aimed to analyze the efficacy of eltrombopag in treating PGF after ASCT.

Methods: Patients receiving eltrombopag for PGF after ASCT between 2017 and 2020 were retrospectively evaluated. Patients' characteristics, details for ASCT, timing, treatment, and possible contributors for PGF, response to eltrombopag treatment, and overall response rate (ORR) were analyzed. Results: Eighteen patients were assessed. Eltrombopag treatment yielded a favorable response in 11 patients, resulting in an ORR of 61%. The ORR in secondary PGF was better than that in primary PGF (83% and 17% respectively). There was a marked enhancement in platelet and hemoglobin levels following eltrombopag treatment ( and , respectively), while neutrophil values exhibited no significant change (). Among the responding patients, four individuals (22%) underwent a tapering and discontinuation of eltrombopag. No toxicity was observed above grade one, and no patient discontinued eltrombopag because of intolerability or adverse events.

Conclusion: Our findings affirm that eltrombopag can treat poor graft function after allogeneic stem cell transplantation without significant toxicities. These results contribute to the growing body of evidence supporting the use of eltrombopag in poor graft function after allogeneic stem cell transplantation, providing insights into its potential benefits and limitations.

Citing Articles

Eltrombopag Enhances Recovery from Cytopenias Due to Poor Graft Function after Hematopoietic Cell Transplantation.

Halahleh K, Al-YaGoub M, Makoseh M, Al-Far R, Dana W, Pharm R Blood Cell Ther. 2025; 8(1):160-166.

PMID: 40061175 PMC: 11883521. DOI: 10.31547/bct-2024-017.

References

Master S, Dwary A, Mansour R, Mills G, Koshy N . Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Case Rep Oncol. 2018; 11(1):191-195. PMC: 5903126. DOI: 10.1159/000487229. View

Liu X, Wu M, Peng Y, Chen X, Sun J, Huang F . Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2013; 23(9):1087-98. DOI: 10.3727/096368912X661319. View

Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M . Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000; 111(1):292-302. DOI: 10.1046/j.1365-2141.2000.02306.x. View

Bittencourt H, Rocha V, Filion A, Ionescu I, Herr A, Garnier F . Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant. 2005; 36(5):431-5. DOI: 10.1038/sj.bmt.1705072. View

Ghobadi A, Fiala M, Ramsingh G, Gao F, Abboud C, Stockerl-Goldstein K . Fresh or Cryopreserved CD34-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2017; 23(7):1072-1077. PMC: 5515540. DOI: 10.1016/j.bbmt.2017.03.019. View

Fattizzo B, Levati G, Cassin R, Barcellini W . Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. Drugs. 2019; 79(12):1305-1319. DOI: 10.1007/s40265-019-01159-0. View

Kircali E, Seval G, Ozturk C, Yilmaz H, Koyun D, Bozdag S . Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data. Balkan Med J. 2022; 40(1):51-56. PMC: 9874246. DOI: 10.4274/balkanmedj.galenos.2022.2022-2-48. View

Tang C, Chen F, Kong D, Ma Q, Dai H, Yin J . Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag. J Hematol Oncol. 2018; 11(1):103. PMC: 6097332. DOI: 10.1186/s13045-018-0649-6. View

Giammarco S, Sica S, Chiusolo P, Laurenti L, Sora F, Martino M . Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. Int J Hematol. 2021; 114(2):228-234. DOI: 10.1007/s12185-021-03153-3. View

10.

Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L . Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019; 54(8):1346-1353. DOI: 10.1038/s41409-019-0442-3. View

11.

Vasudevan Nampoothiri R, Kumar R . Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation. Indian J Hematol Blood Transfus. 2020; 36(2):238-245. PMC: 7229069. DOI: 10.1007/s12288-019-01194-7. View

12.

Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View

13.

Yuan C, Boyd A, Nelson J, Patel R, Varela J, Goldstein S . Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(7):1320-1324. DOI: 10.1016/j.bbmt.2019.01.027. View

14.

Aydin S, Dellacasa C, Manetta S, Giaccone L, Godio L, Iovino G . Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation. Ther Adv Hematol. 2020; 11:2040620720961910. PMC: 7594218. DOI: 10.1177/2040620720961910. View